Nanoscope wins Japan designations

Nanoscope Therapeutics said on January 20 that Japan’s Ministry of Health, Labour and Welfare granted its retinal gene therapy candidate MCO-010 both Sakigake and Orphan Drug designations. The company said the dual designations cover inherited retinal diseases and make MCO-010 the first retinal gene therapy to receive both in Japan. Ophthalmology Times, citing the company, said the decision gives the program access to Japan’s fast-track pathway for regenerative medicines. (nanostherapeutics.com) Japan’s Sakigake program is designed for innovative therapies aimed at serious unmet needs and can provide prioritized consultation and review with the Pharmaceuticals and Medical Devices Agency, according to Nanoscope. (nanostherapeutics.com) The company said Orphan Drug status in Japan applies to therapies for fewer than 50,000 patients with high medical need. Samarendra Mohanty, Nanoscope’s president and chief scientific officer, said in the company release that the designations were “another pivotal milestone” for the program. (nanostherapeutics.com) ### What exactly did Japan grant, and why does Nanoscope care? Japan’s health ministry granted two separate regulatory designations to the same product candidate. Nanoscope said Sakigake is the country’s premier fast-track route for novel therapies, while Orphan Drug designation is intended for rare conditions with high unmet need. The company said the combination creates an accelerated regulatory path for MCO-010 in Japan and may support premium pricing after approval. (nanostherapeutics.com) January 20 was also the date Nanoscope said the designations extended its broader regulatory push across major markets. Ophthalmology Times reported that MCO-010 has also received five orphan designations from the European Medicines Agency and multiple expedited-program designations from the U.S. Food and Drug Administration. (nanostherapeutics.com) ### What is MCO-010 supposed to do in the eye? MCO-010 is an optogenetic therapy delivered as a one-time intravitreal injection, according to Nanoscope and Ophthalmology Times. The therapy is designed to restore light sensitivity by activating bipolar retinal cells that remain after photoreceptors have degenerated. Ophthalmology Times said the company is developing it for conditions including retinitis pigmentosa, Stargardt disease and geographic atrophy. (nanostherapeutics.com) Retinitis pigmentosa is one of several inherited retinal diseases marked by progressive vision loss. The Foundation Fighting Blindness says CRB1 mutations are among the relatively common genetic causes of inherited retinal degeneration and are linked to retinitis pigmentosa, Leber congenital amaurosis and macular dystrophy. ### What evidence has Nanoscope put forward so far? (ophthalmologytimes.com) Ophthalmology Times reported that long-term data from the EXTEND and REMAIN studies showed lasting safety and meaningful vision gains for MCO-010. Nanoscope said in October 2025 that the REMAIN follow-up study showed sustained three-line vision gains from baseline through 152 weeks in patients with severe vision loss from retinitis pigmentosa, with a favorable safety profile. November 2025 data from the EXTEND follow-up study covered 10 patients with advanced retinitis pigmentosa who had previously received a single intravitreal injection of MCO-010. (nanostherapeutics.com) Ophthalmology Times reported that the company said the five-year follow-up found no serious adverse effects or new safety signals. ### Why does CRB1 testing keep coming up around inherited-retinal therapy? (fightingblindness.org) CGTlive reported in June 2023 that researchers at Australia’s Lions Eye Institute were studying how CRB1 variants affect gene expression using CRISPR activation in patient-derived fibroblasts. Sang Yoon Moon, a postdoctoral research associate at the institute, said the work was aimed at helping resolve uncertain genetic findings that can leave patients without a full molecular diagnosis. The same report said uncertain variants can keep patients out of future clinical trials because pathogenicity has to be established before enrollment. (ophthalmologytimes.com) Moon said the institute’s biobank and genetic monitoring work are used to help patients access trials, and CGTlive said the platform could be applied more broadly to screen novel variants across inherited retinal diseases. ### What happens next for MCO-010? July 14, 2025, was the date Nanoscope said it began a rolling biologics license application to the FDA for MCO-010 in retinitis pigmentosa. (ophthalmologytimes.com) The company said the application was eligible for priority review under Fast Track and that full submission was anticipated in early 2026. Nanoscope also said in its Japan announcement that the MOGENRY brand name had been conditionally approved by the FDA, the European Medicines Agency and Japan’s PMDA. (cgtlive.com) Japan’s next formal steps would run through the Pharmaceuticals and Medical Devices Agency under the Sakigake pathway, according to the company. In parallel, patient selection for inherited-retinal studies continues to depend on molecular diagnosis in mutation-specific programs, while Nanoscope is positioning MCO-010 as a gene-agnostic option for severe vision loss from retinal degeneration. (nanostherapeutics.com 1) (nanostherapeutics.com 2) (cgtlive.com)